Although authoritative health and medical entities recommend comprehensive lifestyle modification as part of the treatment plan for obesity, the use of such therapies before or to support GLP‐1 use is not widespread in practice. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.